Evidence map›Paper›PMID 26045796›Full record

ArticleInternational journal of clinical and experimental pathology2015

Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.

Jinyang Gu, Shu Zhang, Xingyu Wu, Jiong Shi, Bin Zhang, Xiaoqi Zhang, Jun Yang, Halmurat Obulkasim, Fei Duan, Chao Deng and 3 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jinyang GuDepartment of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China ; Jiangsu Clinical Medical Center of Digestive Disease Nanjing 210008, China ; Jiangsu Province's Key Medical Center for Liver Surgery Nanjing 210008, China ; Institute of Hepatobiliary Surgery, Nanjing University Nanjing 210008, China.
Shu ZhangDepartment of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China ; Jiangsu Clinical Medical Center of Digestive Disease Nanjing 210008, China.
Xingyu WuDepartment of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China ; Jiangsu Clinical Medical Center of Digestive Disease Nanjing 210008, China ; Jiangsu Province's Key Medical Center for Liver Surgery Nanjing 210008, China ; Institute of Hepatobiliary Surgery, Nanjing University Nanjing 210008, China.
Jiong ShiDepartment of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China.
Bin ZhangDepartment of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China ; Jiangsu Clinical Medical Center of Digestive Disease Nanjing 210008, China.
Xiaoqi ZhangDepartment of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China ; Jiangsu Clinical Medical Center of Digestive Disease Nanjing 210008, China.
Jun YangDepartment of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China.
Halmurat ObulkasimDepartment of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China.
Fei DuanDepartment of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China.
Chao DengDepartment of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China ; Jiangsu Clinical Medical Center of Digestive Disease Nanjing 210008, China.
Jing HeNanjing University of Chinese Medicine Nanjing 210000, China.
Xiaoping ZouDepartment of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China ; Jiangsu Clinical Medical Center of Digestive Disease Nanjing 210008, China.
Yitao DingDepartment of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing 210008, China ; Jiangsu Clinical Medical Center of Digestive Disease Nanjing 210008, China ; Jiangsu Province's Key Medical Center for Liver Surgery Nanjing 210008, China ; Institute of Hepatobiliary Surgery, Nanjing University Nanjing 210008, China.
Nanjing Drum Tower Hospital · CNNanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant fibrous histiocytoma (MFH) of the breast and visceral organs is extremely rare. There is an incomplete understanding of the clinical pathology of the primary MFH originating from the breast and visceral organs, especially in comparison with other soft tissue sarcomas. As a consequence we searched and analyzed the clinical and pathological records of all the nine patients with diagnosed breast and visceral MFH in our hospital. Immunohistochemical staining was performed for ezrin and HMG-CoA reductase in these MFH cases and relevant mesenchymal sarcomas. The 9 MFH cases presented with nonspecific symptoms and imaging manifestations. 6 cases were classified as storiform-pleomorphic MFH, 2 cases as inflammatory MFH, and the remaining 1 case as giant cell MFH. The results showed that ezrin expression, as well as HMG-CoA reductase expression, was significantly stronger in MFH cases than other non-MFH sarcomas. Poor prognosis seemed to be associated with younger age. Certain characteristics and clinicopathologic features can help us making the diagnosis of MFH. In conclusion, our study provided the potential value of ezrin and HMG-CoA reductase for diagnosis and differential diagnosis of MFH located in the breast and visceral organs. More accurate prognostic information of this rare disease needed to be further investigated.

Indexed as

AdultAgedBiomarkers, TumorCytoskeletal ProteinsEzrinFemaleHistiocytoma, Malignant FibrousHumansHydroxymethylglutaryl CoA ReductasesImmunohistochemistryMaleMiddle AgedVisceraBiomarkers, TumorCytoskeletal ProteinsEzrinHydroxymethylglutaryl CoA ReductasesbreastezrinHMG-CoA reductaseMalignant fibrous histiocytomavisceral organs

Identifiers

PMID26045796
PMCPMC4440105
OpenAlexW637055856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.